SH3RF3 Antibody

What is SH3RF3 and what functional domains should researchers target with antibodies?

SH3RF3 (SH3 Domain Containing Ring Finger 3) is a scaffold protein with multiple functional domains that plays critical roles in signaling pathways relevant to neuroinflammation and neurodegeneration. The protein contains four SH3 domains involved in protein-protein interactions, a novel Rac1 binding domain that specifically interacts with active GTP-bound Rac1, and a RING domain conferring E3 ligase activity that enables self-targeting and potentially other proteins for proteasomal degradation . When selecting antibodies for SH3RF3 research, targeting the C-terminal region provides specificity for distinguishing SH3RF3 from other SH3RF family members (SH3RF1/POSH and SH3RF2/POSHER), as commercially available antibodies often target peptides corresponding to C-terminal amino acids . Understanding these domains is crucial for experimental design, as domain-specific antibodies will provide different insights into protein interactions and functions.

How does SH3RF3 expression differ between human and mouse tissues, and what implications does this have for translational research?

SH3RF3 demonstrates notable species-specific expression patterns that researchers must consider when translating findings between model systems. In the human brain, SH3RF3 shows highest expression in microglia and fetal astrocytes . Contrastingly, in mouse brain, SH3RF3 expression is predominantly in neurons with relatively low expression in microglia . This fundamental difference has significant implications for translational research:

• Mouse models may not accurately recapitulate human SH3RF3 function in microglial-mediated neuroinflammation

• Researchers should validate findings across species and consider human cell models

• Antibody selection must account for these expression differences when designing immunohistochemistry experiments

These expression differences likely explain why human microglia demonstrate unique cytokine response modules to amyloid that are not observed in murine microglia, with SH3RF3 being identified as a member of cytokine response module 2 (CRM2) . When designing experiments, researchers should consider using human iPSC-derived microglia to better represent human disease pathophysiology.

What applications are validated for commercial SH3RF3 antibodies?

Commercial SH3RF3 antibodies have been validated for multiple experimental applications with varying levels of optimization. Researchers should select antibodies based on their specific experimental requirements:

Most antibodies show reactivity against human and mouse SH3RF3, with predicted cross-reactivity to bovine, horse, sheep, rabbit, and dog . When selecting an antibody, researchers should verify the validation data for their specific application and consider whether conjugated versions (such as FITC, PE, APC, or Biotin conjugates) might be beneficial for multicolor analysis .

How can researchers utilize SH3RF3 antibodies to investigate its role in Alzheimer's disease pathogenesis?

Recent research has identified SH3RF3 as a key microglial-expressed positive regulator in late-onset Alzheimer's disease (LOAD) pathogenesis, with genetic variants that lower expression being associated with delayed disease onset . To investigate its role in AD, researchers can employ SH3RF3 antibodies in several sophisticated experimental approaches:

• Phosphorylation status analysis: Use phospho-specific antibodies alongside total SH3RF3 antibodies to examine JNK pathway activation in response to amyloid beta. Studies show SH3RF3 knockdown decreases tau phosphorylation at Ser422, a JNK-specific site .

• Co-immunoprecipitation experiments: Employ SH3RF3 antibodies to pull down protein complexes and identify binding partners in the JNK and NFκB signaling cascades under different experimental conditions (baseline vs. inflammatory stimulus).

• Tissue microarray analysis: Apply SH3RF3 antibodies in IHC to examine expression patterns in post-mortem AD brain tissues compared to controls, with particular focus on microglial expression in amyloid plaque-adjacent regions.

• Live cell imaging: Use fluorescently-conjugated SH3RF3 antibodies in permeabilized cells to track subcellular localization changes following inflammatory stimulation with oligomeric Aβ42 or poly(I:C).

The experimental design should include appropriate controls and consider that SH3RF3 effects may be cell-type specific, with more pronounced inflammatory modulation in microglia compared to neurons .

What methodological approaches can validate SH3RF3 knockdown efficiency in neuroinflammation studies?

Validating SH3RF3 knockdown is critical for reliable interpretation of functional studies. Researchers studying SH3RF3's role in neuroinflammation should implement a multi-method validation approach:

• Transcript quantification: qPCR remains the gold standard for measuring knockdown efficiency at the mRNA level, as demonstrated in both neuronal and microglial models .

• Protein detection: Western blotting using validated SH3RF3 antibodies provides confirmation at the protein level. When performing Western blots, researchers should:

  • Include appropriate loading controls

  • Quantify band intensity using densitometry

  • Present data as fold-change relative to control conditions

• Functional validation: Measure alterations in downstream pathway components, such as reduced phosphorylation of JNK and p65 subunit of NFκB in response to inflammatory stimuli following SH3RF3 knockdown .

• Inflammatory cytokine profiling: Quantify changes in inflammatory cytokine production (e.g., TNF-α, IL-6, IL-1β) in response to stimuli like poly(I:C) or oligomeric Aβ42, which should be attenuated with successful SH3RF3 knockdown .

For comprehensive validation in microglia studies, researchers should perform transcriptomic analysis to identify differential gene expression patterns associated with SH3RF3 knockdown, as this has revealed broader functional impacts beyond immediate signaling pathways .

How can SH3RF3 antibodies be used to distinguish between the three SH3RF family members in experimental systems?

Distinguishing between SH3RF family members (SH3RF1/POSH, SH3RF2/POSHER, and SH3RF3/POSH2) is essential for accurate functional characterization. These proteins share similar domain structures but have distinct functions, with SH3RF1 and SH3RF3 both serving as JNK pathway scaffolds while SH3RF2 lacks the SH3 domain . Researchers can implement these approaches:

• Epitope selection: Choose antibodies targeting unique regions, particularly C-terminal epitopes, as commercial SH3RF3 antibodies often target the C-terminal region (amino acids 801-829) .

• Validation with recombinant proteins: Perform Western blot analysis using recombinant proteins of all three family members to confirm antibody specificity.

• Knockout/knockdown controls: Include SH3RF3-specific knockdown samples as negative controls and test for cross-reactivity with other family members.

• Sequential immunoprecipitation: To analyze complex samples, deplete SH3RF1 and SH3RF2 first, then probe for remaining SH3RF3, or use a panel of family-specific antibodies in parallel.

• Mass spectrometry validation: For definitive identification in complex samples, follow immunoprecipitation with mass spectrometry to confirm protein identity based on unique peptide sequences.

When studying interactions between family members, such as SH3RF2's reported targeting of SH3RF1 for proteasomal degradation, researchers must carefully select antibodies that do not cross-react to accurately assess these regulatory relationships .

What controls should researchers implement when studying SH3RF3's role in microglial activation?

When investigating SH3RF3's role in microglial activation, rigorous controls are essential to ensure experimental validity and reproducibility. Based on recent research approaches, implement these critical controls:

• Knockdown validation controls:

  • Non-targeting siRNA/shRNA control groups

  • Multiple siRNA sequences targeting different regions of SH3RF3 to rule out off-target effects

  • qPCR and Western blot confirmation of knockdown efficiency

• Pathway validation controls:

  • Pharmacological inhibitors of JNK (e.g., SP600125) and NFκB pathways as positive controls to phenocopy SH3RF3 knockdown effects

  • Assessment of pathway activation markers (phospho-JNK, phospho-p65) in parallel with functional outcomes

• Cellular phenotype controls:

  • Time-course analysis of microglial activation markers

  • Comparison between different activation stimuli (oligomeric Aβ42 versus poly(I:C))

  • Assessment of multiple inflammatory cytokines rather than single markers

• Species-specific considerations:

  • Include both human and mouse microglial models when possible, given the species-specific expression patterns of SH3RF3

  • For translational relevance, prioritize human iPSC-derived microglia (iMGLs) which exhibit unique cytokine response modules to amyloid not seen in murine models

Recent studies emphasize that human microglia demonstrate distinct inflammatory signatures compared to mouse models, with SH3RF3 being identified as a component of these human-specific responses .

What technical optimizations are required for using SH3RF3 antibodies in phosphorylation studies relevant to JNK pathway activation?

Studying SH3RF3's role in JNK pathway activation requires careful technical optimization of phosphorylation detection. Researchers should consider:

• Sample preparation optimization:

  • Rapid sample collection and processing to preserve phosphorylation status

  • Use of phosphatase inhibitors in lysis buffers

  • Standardized stimulation protocols for JNK activation (duration and concentration of stimuli)

• Antibody selection strategy:

  • Primary SH3RF3 antibody validated for detecting total protein

  • Phospho-specific antibodies for downstream targets (p-JNK, p-c-Jun)

  • Phospho-tau S422 antibody as a functional readout for JNK activity

• Analytical approaches:

  • Parallel detection of total and phosphorylated proteins for proper normalization

  • Quantitative densitometry with time-course analysis

  • Cell fractionation to distinguish cytoplasmic versus nuclear phospho-protein localization

• Validation experiments:

  • Phosphatase treatment of control samples to confirm specificity of phospho-antibodies

  • JNK inhibitor treatment as positive control for reduced phosphorylation

  • Lambda phosphatase controls for complete dephosphorylation baseline

Research has demonstrated that SH3RF3 knockdown reduces JNK pathway activation in response to inflammatory stimuli, with corresponding reductions in phosphorylation of downstream targets . These effects can be phenocopied by pharmacological inhibition of JNK signaling, providing important control conditions for such studies .

How should researchers design experiments to study SH3RF3's E3 ligase activity using antibody-based approaches?

SH3RF3 contains a RING domain conferring E3 ligase activity that enables self-targeting and potentially targeting other proteins for proteasomal degradation . To study this activity:

• Ubiquitination assays:

  • Immunoprecipitate SH3RF3 using validated antibodies

  • Probe for ubiquitin chains using anti-ubiquitin antibodies

  • Include proteasome inhibitors (MG132) to accumulate ubiquitinated substrates

  • Use K48 and K63 linkage-specific ubiquitin antibodies to distinguish degradative versus non-degradative ubiquitination

• Substrate identification:

  • Perform co-immunoprecipitation using SH3RF3 antibodies followed by mass spectrometry

  • Compare proteomes of wild-type versus RING domain mutants to identify differential substrate accumulation

  • Validate potential substrates with targeted Western blotting

• Domain-specific analysis:

  • Compare wild-type SH3RF3 with RING domain mutants (typically H→A mutations in zinc coordination residues)

  • Assess self-ubiquitination as a readout of E3 ligase activity

  • Monitor SH3RF3 stability and turnover rates using cycloheximide chase assays

• In vitro reconstitution:

  • Use purified components (E1, E2, SH3RF3, potential substrates)

  • Monitor ubiquitination using Western blotting with SH3RF3 antibodies

  • Validate with mass spectrometry to identify ubiquitination sites

The study of SH3RF3's E3 ligase activity is particularly relevant because it may regulate its own abundance and function in inflammatory signaling pathways implicated in Alzheimer's disease pathogenesis .

How can SH3RF3 antibodies contribute to understanding genetic variants that modify Alzheimer's disease risk?

Genetic studies have identified protective variants in SH3RF3 that delay the onset of Alzheimer's disease, particularly in individuals carrying the PSEN1 G206A mutation, with one variant (rs6542814) delaying onset by approximately 9.2 years . Researchers can leverage SH3RF3 antibodies to understand these genetic effects through:

• Expression quantitative trait loci (eQTL) validation:

  • Compare SH3RF3 protein levels in patient-derived cells carrying protective versus risk alleles using calibrated Western blotting

  • Correlate protein expression with genotype data in large sample cohorts

  • Perform immunohistochemistry on post-mortem brain tissue from genotyped donors

• Functional characterization:

  • Assess JNK and NFκB pathway activation in cells with different SH3RF3 genotypes

  • Measure inflammatory cytokine production in response to Aβ or other stimuli

  • Analyze tau phosphorylation patterns at the JNK-specific site Ser422

• Structure-function analysis:

  • Determine if protective variants affect specific domains of SH3RF3 using domain-specific antibodies

  • Examine potential alterations in protein-protein interactions within the JNK scaffold complex

  • Assess changes in E3 ligase activity or protein stability

Combining genomic data with protein-level analyses using SH3RF3 antibodies provides mechanistic insights into how genetic variants modify disease risk, potentially identifying new therapeutic targets for Alzheimer's disease .

What methodological approaches should researchers use when studying SH3RF3's role in human versus mouse models of neuroinflammation?

Given the species-specific differences in SH3RF3 expression patterns—predominantly in microglia in humans but in neurons in mice —researchers must employ tailored methodological approaches:

Recent research has demonstrated that human microglia possess unique cytokine response modules to amyloid that are not observed in murine microglia, with SH3RF3 specifically identified as a component of these human-specific inflammatory responses (cytokine response module 2) . This highlights the importance of selecting appropriate model systems when studying neuroinflammatory processes regulated by SH3RF3.

How can transcriptomic data guide more effective use of SH3RF3 antibodies in functional studies?

Transcriptomic analysis of SH3RF3 knockdown has identified 31 differentially expressed genes in human neurons, including eight genes previously associated with genetic effects on AD risk . Researchers can leverage this information to design more targeted antibody-based studies:

• Multi-protein profiling:

  • Use SH3RF3 antibodies in combination with antibodies targeting differentially expressed proteins

  • Develop multiplex immunofluorescence panels for co-expression analysis

  • Perform sequential immunoprecipitation to identify protein complexes

• Pathway-focused analysis:

  • Target proteins within enriched GO terms (ubiquitin protein ligase activity, metal ion binding)

  • Design co-immunoprecipitation experiments based on predicted protein interactions

  • Validate transcriptionally altered pathways at the protein level

• Temporal dynamics studies:

  • Examine the kinetics of SH3RF3 expression and pathway activation

  • Time-course analysis of protein expression changes following SH3RF3 manipulation

  • Correlate temporal transcriptomic changes with protein-level alterations

By integrating transcriptomic data with protein-level analyses using SH3RF3 antibodies, researchers can develop more comprehensive models of how SH3RF3 influences cellular function in both physiological and pathological contexts, particularly in Alzheimer's disease and neuroinflammation research .